Calithera Biosciences Inc. (CALA) Stock Price Down 2.8%
Calithera Biosciences Inc. (NASDAQ:CALA)’s share price traded down 2.8% during trading on Wednesday . The company traded as low as $3.02 and last traded at $3.08, with a volume of 113,033 shares changing hands. The stock had previously closed at $3.17.
Separately, JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a report on Wednesday, June 8th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Calithera Biosciences has a consensus rating of “Buy” and a consensus price target of $10.38.
The company’s 50-day moving average price is $3.15 and its 200 day moving average price is $4.40. The stock’s market capitalization is $61.98 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/calithera-biosciences-inc-cala-stock-price-down-2-8.html
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.03. Equities analysts expect that Calithera Biosciences Inc. will post ($2.16) EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in CALA. Paloma Partners Management Co bought a new position in Calithera Biosciences during the second quarter worth about $150,000. GSA Capital Partners LLP raised its position in Calithera Biosciences by 25.9% in the second quarter. GSA Capital Partners LLP now owns 43,800 shares of the company’s stock worth $162,000 after buying an additional 9,000 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Calithera Biosciences during the first quarter worth about $218,000. Geode Capital Management LLC raised its position in Calithera Biosciences by 6.9% in the first quarter. Geode Capital Management LLC now owns 66,250 shares of the company’s stock worth $376,000 after buying an additional 4,286 shares in the last quarter. Finally, Bridgeway Capital Management Inc. raised its position in Calithera Biosciences by 102.8% in the second quarter. Bridgeway Capital Management Inc. now owns 157,850 shares of the company’s stock worth $586,000 after buying an additional 80,000 shares in the last quarter. 48.26% of the stock is currently owned by hedge funds and other institutional investors.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.